Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid ...

Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by Bloomberg Law. The suit, filed ...

Sage Group plc has confirmed it temporarily suspended its Sage Copilot, an AI assistant for the UK-based business software maker's accounting tools, this month after it blurted customer information to ...

Sage Ther­a­peu­tics has sued Bio­gen in Delaware court, one week af­ter re­ceiv­ing a $469 mil­lion buy­out of­fer from the larg­er neu­ro­science phar­ma com­pa­ny.

Sage is a popular culinary herb that is packed with beneficial nutrients such as Calcium and Vitamin K which help reduce blood sugar levels, ease menopause symptoms. There is little research about ...

Sage emphasised that there is no certainty the proposal from Biogen will result in a transaction. Credit: skynesher via Getty Images. Biogen has made an unsolicited offer to acquire its partner Sage ...

Late last week, Biogen made an unsolicited offer to buy one of its partners, brain drug developer Sage Therapeutics. The two biotechnology companies have worked together over the past four years on a ...

Mysuru’s favorite and largest circulated English evening daily has kept the citizens of Mysuru informed and entertained since 1978. Over the past 45 years, Star of Mysore has been the newspaper that ...

Having witnessed a 90%-plus stock price slide during recent years, Sage Therapeutics’ leadership must decide whether now is the right time to accept a buyout offer. Biogen has offered to ...

Sage Therapeutics (NASDAQ:SAGE) has confirmed that the Alzheimer’s drug developer Biogen (NASDAQ:BIIB) has offered to buy all the outstanding shares of common stock that it currently does not ...